Daniel Wolfram
Trump has used intimidation tactics and a slew of threats to secure these low prices.
Ever since Trump took office for a second time nearly two years ago, he has been searching for a decisive victory he can hang his hat on, especially with the midterm elections coming in November.
Data showing a steep fall in one particular area might just give him the victory he needs.
But it comes with threats, stipulations, and an argument over whether Trump is really the person who should receive credit.
Drug prices take a fall
White House officials are boasting about a 3.1 percent decrease in prescription medicine costs over the past year. According to them, this drop marks the steepest annual price decline for pharmaceuticals since 1963.
The victory lap has already begun. According to the New York Post, government officials credit aggressive pressure on major drugmakers for driving down rates across the country.
Under the new policy push, officials threatened international drug giants with crippling tariffs unless they matched the lower rates charged in other first-world countries.
Executive office deals
That tariff threat quickly brought results. Corporate executives soon traveled to Washington for high-profile meetings with Trump personally to pledge voluntary price cuts.
A new platform called TrumpRx now lists lower prices for patients who lack health insurance. Working alongside Medicare administrator Dr. Mehmet Oz, the administration also secured discount promises for popular weight-loss treatments, including Ozempic and Wegovy.
Debate over credit
Campaign strategists are already turning these cost cuts into a central message for the upcoming November midterm elections. But a feud over who deserves the credit is growing.
Axios reported that earlier Medicare price negotiations started under former President Joe Biden may have helped drive the price drop.
The White House rejected that explanation. Spokesman Kush Desai told Axios that connecting the current savings to previous policies was “idiotic and unfounded.”
More confrontation lies ahead. Officials plan to haul in health insurance company leaders next, pressuring executives to trim profit margins across the entire sector.
